Literature DB >> 17928984

[Sentinel node dissection in prostate cancer: current status].

D Weckermann1, G Holl, T Wagner, R Harzmann.   

Abstract

Sentinel lymph node (SLN) dissection is an excellent staging procedure with high sensitivity (>95%) for detecting positive nodes. When the sentinel node is negative, there is high certainty that other lymph nodes are also negative. Limitations of this technique include the use of hormone therapy over several months and a preceding transurethral resection or suprapubic adenomectomy. When sentinel node dissection is performed in patients with intermediate and high-risk prostate cancer, it should be kept in mind that when the SLN is positive, other lymph nodes can be positive, too. The positive non-SLN can be located outside the SLN region. Therefore, both sentinel and extended lymph node dissection should be used in men with a higher risk of lymph node metastases.

Entities:  

Mesh:

Year:  2007        PMID: 17928984     DOI: 10.1007/s00120-007-1564-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  28 in total

1.  Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <10 ng/ml undergoing radical prostatectomy for prostate cancer?

Authors:  Fiona C Burkhard; Martin Schumacher; George N Thalmann; Urs E Studer
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

2.  Laparoscopic sentinel lymph node dissection--a novel technique for the staging of prostate cancer.

Authors:  Stefan Corvin; David Schilling; Kai Eichhorn; Ilse Hundt; Joerg Hennenlotter; Aristotelis G Anastasiadis; Markus Kuczyk; Roland Bares; Arnulf Stenzl
Journal:  Eur Urol       Date:  2005-12-09       Impact factor: 20.096

3.  Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients.

Authors:  Christian J Haas; Theodor Wagner; Friedhelm Wawroschek; Hans Arnholdt
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

4.  [Sentinel lymph node diagnosis in prostatic carcinoma: II. Biokinetics and dosimetry of 99mTc-Nanocolloid after intraprostatic injection].

Authors:  H Wengenmair; J Kopp; H Vogt; F Wawroschek; S Gröber; R Dorn; P Heidenreich
Journal:  Nuklearmedizin       Date:  2002-04       Impact factor: 1.379

5.  Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer.

Authors:  Stephan Jeschke; Avi Beri; Martin Grüll; Josef Ziegerhofer; Peter Prammer; Karl Leeb; Wolfgang Sega; Guenter Janetschek
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

6.  Radioisotope guided pelvic lymph node dissection for prostate cancer.

Authors:  F Wawroschek; H Vogt; D Weckermann; T Wagner; M Hamm; R Harzmann
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

7.  Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.

Authors:  Dorothea Weckermann; Robert Dorn; M Trefz; Theodor Wagner; Friedhelm Wawroschek; Rolf Harzmann
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

8.  Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.

Authors:  Axel Häcker; Stefan Jeschke; Karl Leeb; Kurt Prammer; Josef Ziegerhofer; Wolfgang Sega; Werner Langsteger; Guenter Janetschek
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

9.  Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases.

Authors:  Friedhelm Wawroschek; Harry Vogt; Hermann Wengenmair; Dorothea Weckermann; Michael Hamm; Mathias Keil; Gerhard Graf; Peter Heidenreich; Rolf Harzmann
Journal:  Urol Int       Date:  2003       Impact factor: 2.089

10.  Recent applications of the sentinel lymph node concept: preliminary experience in prostate cancer.

Authors:  M Rudoni; G M Sacchetti; L Leva; E Inglese; G Monesi; D Minocci; B Frea
Journal:  Tumori       Date:  2002 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.